CJC-1295 (No DAC)
Also known as: CJC-1295 DAC, CJC-1295 no DAC, Modified GRF 1-29
Key Facts: CJC-1295 (No DAC)
- Category
- Growth Hormone
- FDA Status
- Not FDA Approved
- Clinical Status
- Investigational - Phase II trial discontinued. Removed from FDA Category 2 in Sept 2024 for PCAC review; expected reclassification to Category 1 (April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026)
- Administration
- Subcutaneous injection
- Typical Dose
- 100 mcg daily (no DAC) or 2 mg weekly (with DAC)
- Frequency
- Daily (no DAC) or 1-2x weekly (with DAC)
- Duration
- 8-12 weeks
Mechanism of Action
CJC-1295 binds to GHRH receptors on the pituitary, stimulating GH synthesis and release. The DAC (Drug Affinity Complex) version binds to albumin, extending half-life to 6-8 days. Without DAC (Mod GRF 1-29), half-life is about 30 minutes.
Research Summary
Phase II trial in HIV lipodystrophy patients was discontinued after a patient death (MI, deemed unrelated but trial ended as precaution). Earlier studies show sustained 2-10 fold increase in GH and IGF-1 levels with good tolerability at doses up to 60 mcg/kg.
Dosing Information
Typical Dosingⓘ
Community experience
100 mcg daily (no DAC) or 2 mg weekly (with DAC)
100-300 mcg per dose (no DAC), 1-2 mg weekly (DAC)
Daily (no DAC) or 1-2x weekly (with DAC)
No-DAC version requires daily dosing. DAC version has longer half-life. Often stacked with GHRP like Ipamorelin.
Research Dosingⓘ
Scientific studies
Doses observed in research studies
Doses from Studies
CJC-1295 DAC: 1-2mg weekly
Mod GRF 1-29: 100-300 mcg 2-3x daily
Duration
8-12 weeks
Administration
Subcutaneous injection
Timing & Administration
Best Time to Take
Before bed
1-2 times per week
Food Recommendation
Take on empty stomach
Why This Timing?
CJC-1295 (with DAC) has a long half-life (~8 days) so timing is less critical, but evening dosing supports natural GH patterns.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Injection site reactions
- ●Facial flushing
- ●Headache
- ●Water retention
- ●Dizziness
- ●May trigger histamine release - use caution with MCAS or histamine sensitivity
- ●Concerns for cancer patients (IGF-1/GH effects)
- ●Risk of immunogenicity
References
- https://pubmed.ncbi.nlm.nih.gov/16352683/
- https://pubmed.ncbi.nlm.nih.gov/17018654/
- https://pubmed.ncbi.nlm.nih.gov/15817669/
Research This Peptide Further
Frequently Asked Questions
What does CJC-1295 (No DAC) do?
A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
How does CJC-1295 (No DAC) work?
CJC-1295 binds to GHRH receptors on the pituitary, stimulating GH synthesis and release. The DAC (Drug Affinity Complex) version binds to albumin, extending half-life to 6-8 days. Without DAC (Mod GRF 1-29), half-life is about 30 minutes.
Is CJC-1295 (No DAC) FDA approved?
No, CJC-1295 (No DAC) is not currently FDA approved. Current status: Investigational - Phase II trial discontinued. Removed from FDA Category 2 in Sept 2024 for PCAC review; expected reclassification to Category 1 (April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026)
What are the side effects of CJC-1295 (No DAC)?
Reported side effects include: Generally well-tolerated, Injection site reactions, Facial flushing, Headache, Water retention. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of CJC-1295 (No DAC)?
Community-reported common dose: 100 mcg daily (no DAC) or 2 mg weekly (with DAC) (Daily (no DAC) or 1-2x weekly (with DAC)). Range: 100-300 mcg per dose (no DAC), 1-2 mg weekly (DAC). Administration: Subcutaneous injection. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with CJC-1295 (No DAC) or used in similar applications.
Ipamorelin
Clinical TrialsA selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.
Growth HormoneGHRP-6
Clinical TrialsOne of the first synthetic GH secretagogues developed. Strongly stimulates GH release and significantly increases appetite through ghrelin receptor activation.
Growth HormoneGHRP-2
Clinical TrialsA synthetic hexapeptide that potently stimulates GH release. More potent than GHRP-6 with less appetite stimulation, but still elevates cortisol and prolactin.
Growth HormoneMK-677
Clinical TrialsAn orally active growth hormone secretagogue that mimics ghrelin. Although technically not a peptide, it is frequently discussed alongside GH peptides due to similar effects.
Growth HormoneTesamorelin
FDAAn FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. New F8 formulation (Egrifta WR) approved March 2025 allows weekly reconstitution vs daily.
Growth HormoneSermorelin
PreclinicalA truncated analog of natural GHRH containing the first 29 amino acids. Previously FDA-approved for pediatric GH deficiency, now used off-label for adult hormone optimization.
Growth HormoneWant updates on CJC-1295 (No DAC) research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.